We cannot fully exclude off-target effects of empagliflozin on atherosclerosis regression but believe it unlikely for the following reasons: First, in a previous study glucose reduction by either SGLT2 inhibition (in this case dapagliflozin) or by SGLT2 antisense oligonucleotide led to similar effects on atherosclerosis and white blood cells in mice5. Here, SLC5A2 is linked to atherosclerosis.